Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. 8. Juni 2017 Schimanski, C.C., Staib, F., Göhler, T., Hebart, H., Heike, M., Neise, M., Rudi, J., Geer, T., Dingeldein, G., Lang, C., Ehscheidt, P., Flohr, T., Josten, K.M., Karthaus, M., Schmittel, A., Wierecky, J., Boller, E., Indorf, M., Wörns, M.-A., Galle, P.R., Moehler, M., 2017. J. Cancer Res. Clin. Oncol. 143(6), 1023–1034. doi:10.1007/s00432-017-2344-3 Abstract Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists. Marschner, N., Müller, L., Münch, A., Blumenstengel, K., Hutzschenreuter, U., Busies, S., 2017. J Oncol Pharm Pract 23(4), 288–295. doi:10.1177/1078155216632379… Weiterlesen Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315. Griesinger, F., Eberhardt, W., Marschner, N., Jänicke, M., Hipper, A., Karatas, A., Sebastian, M., Thomas, M., Schirmacher, P., 2017. J Thorac Oncol 12(1)(MA08.02), S385. doi:10.1016/j.jtho.2016.11.435… Weiterlesen